Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the U.S.

Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the collaboration agreement so that Sanofi has full commercial control of nirsevimab in the U.S.

Sanofi has simultaneously entered into a direct royalty agreement with Sobi to share a portion of U.S. net sales from nirsevimab.

With respect to territories outside the U.S., the existing collaboration agreement between AstraZeneca and Sanofi continues to govern that relationship.

The new and updated contractual agreements do not impact nirsevimab registration and launch in the U.S., where all parties remain committed to making Beyfortus available for all infants in time for the 2023/24 RSV season.